England to Open New National Park to Preserve Nature

People exercise in Victoria Park in east London on April 24, 2020. (Photo by Tolga AKMEN / AFP)
People exercise in Victoria Park in east London on April 24, 2020. (Photo by Tolga AKMEN / AFP)
TT

England to Open New National Park to Preserve Nature

People exercise in Victoria Park in east London on April 24, 2020. (Photo by Tolga AKMEN / AFP)
People exercise in Victoria Park in east London on April 24, 2020. (Photo by Tolga AKMEN / AFP)

England will get a new national park as part of a government set of "nature pledges" to give greater access and protection to the countryside.

According to BBC, Natural England will consider a list of possible sites, which could include the Chilterns, the Cotswolds and Dorset.

Some environmentalists gave the news a cautious welcome, as government funding for national parks has fallen in real terms, forcing service and staff cuts.

Funding worth £15m was also announced for a range of protected landscapes. That will be shared by England's 10 existing national parks and 34 National Landscapes, formerly known as Areas of Outstanding Natural Beauty.

The package forms part of the government's final response to a 2019 review that criticized how such protected landscapes were managed and funded.

Julian Glover, the author of the Landscapes Review, which had called for three new national parks to be created, in the Chilterns, Cotswolds and Dorset, said he was thrilled to have "real progress backed with some extra money to help our national landscapes and national parks do more for people and more for nature.”

"They are beautiful places that lift our souls and should be full of life but we now need to find new and greater ambition to support a nation which needs them to thrive," he added.

But Dr. Rose O'Neill, chief executive of the Campaign for National Parks, said the existing parks had suffered a 40% cut in real terms funding since 2010 and were being "financially throttled.”

“"Today's investment will go some way to easing the burden in the short term but the next crisis could be just around the corner," she said.

Parks across the country have had to make cuts to staffing levels and visitor services as their core grant from government has fallen in real terms.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”